Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Czechia

Coordination and Support Action · Running

REACT-CK1 Revolutionizing AML Therapy - A First-in-Class CK1 Inhibitor for Relapsed Refractory Patients

Coordinator
Casinvent Pharma A.s., Czechia
Runs
1 August 2026 to 31 July 2028
Status
Running
EU funding
€485k
Total cost
—
Partners
1 organisations in 1 countries
Type
Coordination and Support Action
Grant agreement
101310805

What the project is doing

In the project's own words, from its summary on CORDIS.

Relapsed or refractory acute myeloid leukaemia (AML) in patients after the state of the art treatment with venetoclax plus azacitidine remains a critical unmet medical need, with median survival often measured in weeks and no approved mutation-agnostic therapeutic options. The compound CI2420B discovered by CasInvent Pharma is a first-in-class, highly potent and selective inhibitor of the kinases CK1α, CK1δ and CK1ε. CI2420B efficiently inhibits both p53-dependent and p53-independent survival pathways including Wnt and other resistance-associated signalling, and demonstrates strong dose-dependent in vivo efficacy in venetoclax-resistant and TP53-altered AML models.

This project aims to progress CI2420B from TRL 4 toward TRL 5/6 by validating the technology in relevant preclinical environments and preparing for first-in-human clinical trials. The work plan includes expanding efficacy testing across genetically diverse AML models, completing the PK/PD and biomarker characterisation, developing scalable CMC processes to generate technical API batches and validated analytical methods, and initiating GLP-enabling toxicology.

Regulatory readiness will be advanced through EMA scientific advice, orphan designation activities, and development of an IMPD/CTA-aligned data package. Clinical positioning and Target Product Profile will be refined with input from EU and US key opinion leaders. CI2420B targets a clearly defined orphan disease segment with extremely poor outcomes and no effective standards of care. Its differentiated mechanism provides a credible route to clinical benefit both as monotherapy and in rational combinations, supporting potential for rapid adoption in specialised treatment centres.

Strong international IP protection (WO2019185631) ensures FTO and partnering potential. Market validation, competitive landscaping, early pricing analogues and focused EU/US go-to-market strategy will reinforce investment readiness and position the project for future EIC-Acc.

Who is involved

OrganisationCityCountryRole
Casinvent Pharma A.s.BrnoCzechiaCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI